Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

This study is testing a combination of three drugs — ruxolitinib, venetoclax, and sometimes azacitidine — in people with acute myeloid leukemia (AML) or secondary AML that has come back or stopped responding to prior treatment. All three drugs target different survival pathways in leukemia cells, and the goal is to find a more effective combination. **You may be eligible if...** - You are 18 or older - You have been diagnosed with AML or secondary AML that has relapsed or stopped responding to treatment - You have received at least one prior therapy for AML - Prior treatment with venetoclax and azacitidine is permitted - Patients with MDS that progressed on treatment may also qualify **You may NOT be eligible if...** - You have certain active infections or serious heart conditions - You are pregnant or breastfeeding - You have had a recent stem cell transplant with active graft-versus-host disease - Your organ function is too low to safely tolerate the study drugs Talk to your doctor to see if this trial is right for you.